Three questions, answered from 121 mapped queries, 43 competitors and 294 customer verbatims. Most figures trace to Palisade_Keyword_Master.xlsx; primary-document and [EST] figures are cited in the full brief's source list. Click any ref marker to see the underlying evidence.
What keywords should anchor the Palisade launch — and what does that mean for every channel?
Two anchors, not one. lactoferrin — 18,000/mo at KD 2 — is the entity anchor: the term that teaches Google, Amazon and the AI answer layer what this brand is. iron gummies — 8,100/mo at KD 0 with a clean parent topic — is the traffic anchor: the cheapest real demand in the category and the best untapped organic target in the project.ref
Do not anchor on colostrum. It is 126,000/mo — and KD 49, declining 33% year on year, ARMRA's brand equity, and untrue of a product that contains no colostrum of any species.ref
| Anchor on colostrum | Anchor on lactoferrin | |
|---|---|---|
| Head-term volume | 126,000/mo | 18,000/mo |
| Head-term difficulty | KD 49 — unwinnable this year | KD 2 — winnable in weeks |
| Trend | −33% YoY | Stable; vegan lactoferrin +240% |
| Whose equity | ARMRA's | Nobody's |
| True of this product | No | Yes |
| Best commercial term available | colostrum supplement KD 11 | iron gummies KD 0, 8,100/mo |
The case for colostrum is real and worth stating: it is three orders of magnitude more demand, the audience is described as colostrum-curious, and category spend grew from $612,000 to over $19M in two years.ref But volume you cannot rank for is not demand, it is scenery. A zero-authority Shopify site does not pass Cleveland Clinic, MD Anderson and Mayo on a KD 49 term this year or next.
The traffic case rests on Ahrefs, and Ahrefs and Google disagree materially on some of these terms — lactoferrin supplement is 1,000 or 6,600; gut health supplement is 2,800 or 33,100. Google buckets close variants and cannot be trusted per keyword, which is why Ahrefs leads here.ref The two are not reconciled in absolute terms. Treat the direction as solid and the precision as not.
| Page | Owns | Primary term | Vol / KD |
|---|---|---|---|
| Homepage | The entity | human lactoferrin | 150 / KD 12 |
| Science page | Informational intent | lactoferrin | 18,000 / KD 2 |
| PDP | Commercial intent | lactoferrin supplement | 1,000 / KD 10 |
/pages/iron-gummies | Traffic | iron gummies | 8,100 / KD 0 |
| Comparison hub | The category question | lactoferrin vs colostrum | 150 / KD 0 |
| Vegan hub | The differentiator | vegan lactoferrin | 50 / KD 0 |
Ahrefs assigns lactoferrin supplement, lactoferrin and lactoferrin benefits the same parent topic. Same-parent pages compete on the same SERP no matter how carefully their title tags differ. Two more collisions exist: gut health supplement shares a parent with its own spoke, and the iron hub's primary ferritin supplement rolls up to low ferritin, which is LOCKED at KD 40.ref
All three are unresolved and need a judgement call, not more research.
One keyword decision, five downstream consequences
The anchor is not an SEO choice that stays in SEO. It sets the product name, the pack, the ad copy, the Amazon node and the feed.
41 pages across three phases, 21 of them before the store opens. Clusters A and C need no product data, so they can be written while dose and packaging are still unresolved.ref
Eight campaigns, twenty launch-day keywords — fifteen with measured bids. Iron entry bids run $0.04–$0.54; gut costs roughly 3–5x more per click on a like-for-like basis.ref
Blended Vitamin & Mineral (3773931). Not Iron (3774401) — that puts a $79 gummy against $8 ferrous sulphate, and Palisade contains no iron. ⚠ Node IDs are [UNVERIFIED] — confirm in Seller Central.ref
Search cannot break this tie — every candidate is 10/mo or no data. So the name is decided on comprehension and claims risk, and "bioidentical" loses on both.ref
The customer's verb is growing +125% YoY while the marketer's word falls −45%. Free to adopt, and it differentiates from five advertisers at once.ref
"vegan lactoferrin", "human lactoferrin", "dairy-free colostrum alternative" — all three currently held by sites with almost no traffic.ref
The anchor decision makes seven phrases in the current deck unusable — unqualified "dairy-free", "bioidentical", "10x more bioavailable", "15x richer in human colostrum", "replaces 15 scoops", the constipation/diarrhea/IBS/leaky-gut hooks, and "inflammation". That is not an SEO constraint; it is every piece of copy the brand will ship.ref
What is our place in this market — and what does it mean for price?
Palisade's position is real but it is not the one the deck describes, and it is not defensible on ingredient. At least eight brands already ship effera, two of them in a chewable. A well-funded competitor launched the same positioning on 27 April 2026.ref What is genuinely unclaimed is narrower: a branded, dosed, human-sequence lactoferrin gummy sold to women with low ferritin.
On price: $79 is defensible only against ARMRA, and only if the dose is published. Every other comparison loses, and the format premium does not exist.ref
ARMRA is the category — 7,600+ doors, 15,837 reviews. But Palisade does not lose customers to ARMRA. It loses them to the lactoferrin brands selling to the same woman.
| Brand | $/day | Dose | Why it matters |
|---|---|---|---|
| Perelel | $2.02 | 250mg (supplier unconfirmed) | Launched Palisade's exact positioning on 27 Apr 2026. $33M raised, OB/GYN founder, already an Erewhon co-branded SKU. ⚠ Their Amazon title says "Lactoferrin from Colostrum," contradicting their own PR. |
| Amulet | $2.30 | 125mg effera | The same physical product at $10 less — gummy, 60ct, 30 days, women, effera — with 3g creatine included. |
| kēpos | $3.00 | not disclosed | ~110 reviews/month [EST] — ten times anyone else. Three AI Overview citation slots and the smartest claims posture in the category. |
An earlier draft of this research argued people pay more for chewables. The workbook refutes it: Vaite Lactoferrin Gummies are 500mg at $22.99/60 = $0.0766 per 100mg — cheaper per milligram than the capsule floor. The cheapest per-milligram lactoferrin product in the entire competitive set is a gummy.ref
Objections rank 1 is price. The only honest angles are arithmetic, not language — the ARMRA per-day comparison and the dose-per-milligram argument. They need a page, not a slogan, and both are blocked until the dose exists.ref
| Option | What it requires | Risk |
|---|---|---|
| Hold $79 and publish a high dose | 250mg+ disclosed in position 2–3 of every title. At 250mg, $0.0105/mg is mid-table among branded human-LF products — beating Amulet, VEEP, Kroma and Healthgevity. | Still ~10–14x commodity bovine per mg. Needs the ARMRA comparison doing real work. |
| Hold $79 with a low or hidden dose | Nothing — it is the current plan. | The worst option. "Dose per serving / underdosed" is the #1 Amazon complaint theme in the category, and three of the competitors who hide their dose are the ones being complained about. |
| Reprice below Amulet's $2.30/day | Sub-$69, or a subscription that lands there. | Concedes the premium position the brand is built on, and Amulet bundles 3g creatine at that price anyway. |
Low ferritin, addressed by a real brand. Three small direct-response advertisers work this space; no major wellness brand does. Nobody says "women 26+" — Perelel and Ritual segment by pregnancy stage, and nobody addresses the non-pregnant woman in her thirties with low ferritin. Combine that with "one molecule, one job" against a category competing on 400+ nutrient counts, and there is a real position there.ref
The AI Overview for are colostrum gummies effective currently says gummies are "unproven… untested, often expensive, and not strictly regulated" — and no brand is contesting it. Original data — a pilot study, a third-party potency assay, a customer ferritin dataset — is the one moat available. The ingredient is not one. The format is not one. The claims are not one.
What are people actually searching — and where can we own the space?
The demand is overwhelmingly in iron, and the winnability is overwhelmingly in lactoferrin. Colostrum is the biggest pool and the least accessible. Gut is the most crowded. The ownable space is the intersection nobody is working: format terms in iron, and the entity terms in lactoferrin.
Of 121 mapped queries, 41 carry a targetable verdict in the workbook and 17 of those sit at KD 0–3. Eleven are locked behind difficulty, and seven are barred on compliance or because their parent topic belongs to a competitor — regardless of what the volume says.
17 is every query at KD 0–3 whose workbook verdict says it can be won. 13 of those already have a page assigned. The four in the gap are real but unbuilt: iron constipation, debloating gummies, gentle iron supplement and vegan colostrum — three of which have a competitor product name as their parent topic, which is why they were left out.
And a third number you will see in the full brief: twelve. That is the narrower set the six-month forecast is built on — page primaries plus one PDP secondary, and it counts armra colostrum reviews (a conquest term, typed Brand here) while excluding the secondaries. Three defensible counts of three different things. Use the In the page plan filter below to see which is which.
The cheapest real demand in the category. But enter through format terms, not symptom terms: low iron fatigue rolls up to "iron deficiency" and low iron hair loss to "iron deficiency hair loss" — both disease parents the red list bars. iron gummies, gentle iron and iron gummies for women are all KD 0 with clean parents.ref
The least defended commercial category in this research. A DR-18 site with four ranking keywords holds #1 for vegan lactoferrin. Palisade's own ingredient supplier holds human lactoferrin on a four-keyword site. ⚠ Heavy diagnostic contamination — seven of the top twenty keywords are stool tests, so negate fecal and stool before any broad match.ref
The biggest pool and the least accessible. Declining, institutionally walled, and ARMRA's equity. Two places it still earns its keep: the comparison page (KD 0, and its AI Overview cites seven sources with no medical publisher among them) and conquest. Never in the product name, the Amazon title or the Shopping feed.ref
IBS and leaky gut are unusable as targets, not just as copy. IBS is a diagnosed disease; NAD struck "prevents and heals gut permeability" in 2010. What survives is the mid-tail — gut health gummies KD 0, gut health supplement KD 8 — deferred to days 90–180 because it needs authority the site won't have.ref
Measured, and it is not a demand engine. But the direction of the one growing term is the whole finding: the vegan interest has attached to lactoferrin, not to colostrum. Use it as the reason-to-believe underneath whichever hook runs — and note it dies entirely if any co-ingredient is bovine.ref
The one benefit territory with a clean claims path — "supports hair, skin and nail health" is the accepted formulation. But the demand is small and falling, and "activates hair growth" is a drug claim FDA cited against A&Z Pharmaceutical in 2023. Worth a section; not worth a cluster.
| # | Opportunity | Vol/mo | KD | Why it is ownable |
|---|---|---|---|---|
| 1 | iron gummies+ the format family | 8,100 | 0 | The best untapped organic target in the project. Clean parent topic, $0.30 CPC, and it sidesteps the disease-claim trap that kills the symptom terms. gentle iron (2,100) and iron gummies for women (1,500) are both KD 0 too. |
| 2 | lactoferrin | 18,000 | 2 | The best volume-to-difficulty term in the whole dataset. A DR-12 site holds #1 today on 335 visits a month. |
| 3 | armra colostrum reviews | 4,000 | 1 | Traffic Potential 26,000, and every related search is dissatisfaction — "reviews and complaints", "negative reviews". ⚠ Paid landing page first: the parent is a competitor brand, so the TP is not organic upside. |
| 4 | lactoferrin vs colostrum | 150 | 0 | The softest SERP in the project. Tiny volume — this is an entity play, not a traffic play. Its AI Overview cites seven sources and not one is a medical publisher, so a brand page can become the cited answer in weeks. |
| 5 | vegan lactoferrin | 50 | 0 | 50 searches a month and +240% YoY. Ahrefs assigns it the parent topic "turtletree" — the category name itself is unclaimed. Blocked on the C2 formula check. |
best iron supplement for anemia is 5,100/mo on Ahrefs (8,100 Google KP) at KD 0 — genuinely winnable and genuinely blocked, because anemia is a diagnosed disease. Same for ibs supplements (2,400), leaky gut supplements (1,900), leaky gut and leaky gut symptoms. These are do-not-bid and do-not-build regardless of what the volume says.
All 121 mapped queries — filter and sort them yourself
Every query this research touched, with Ahrefs volume and difficulty where measured, Google's cluster figure and bid range, the parent topic, and a verdict. Sorted by opportunity: volume discounted by difficulty, scored only for terms that are genuinely targetable.
Do not sum the volume column. Google Keyword Planner buckets close variants and reports the same figure for distinct terms — three separate debloat terms land in one 1,900–2,900 bucket while Ahrefs separates them at 80/200/450. Summing bucketed figures double-counts, and every early "pool total" in this project was an artefact of it.
Parent topic is the column that changed the plan. It is the query Google treats as canonical for a SERP. A page cannot rank for low iron fatigue without Google reading it as an iron-deficiency page — which is why terms with a ⚠ next to their parent are flagged even when their own difficulty looks easy.
| Query▲▼ | Territory▲▼ | Vol/mo Ahrefs▲▼ |
Google ceiling▲▼ |
KD▲▼ | Traffic potential▲▼ |
Entry bid▲▼ |
Verdict▲▼ | Opp.▲▼ |
|---|
◆ marks a term the launch page plan actually builds for. † marks a difficulty score carried from the Module 2 Ahrefs paid pull rather than the premium 50. Verdict comes from the workbook's own Keyword_Ownership column, not from an inference here.
Opportunity = Ahrefs volume discounted by the square of difficulty, scored only for targetable terms. It is a sorting aid, not a forecast — a KD 0 term still needs the best page on the SERP to win.
Five decisions block launch — and none of them is a research problem
| Ref | Decision | What it blocks | Owner |
|---|---|---|---|
| P1 | What is the lactoferrin dose per serving? Not stated anywhere in the deck. | All price anchoring, any efficacy claim, the PDP title tag and the Amazon title — which literally contain [X]mg. And the single biggest differentiator available, since three effera competitors hide their dose. | Product |
| C1 | Does yeast-expressed human-sequence lactoferrin trigger milk-allergen labelling? | Every ad, bullet and pack. The highest-risk claim in the deck. Needs FDA regulatory counsel — not more desk research. | Legal |
| C2 | Does the formula contain any bovine-derived co-ingredient? | The word "vegan" everywhere, the entire vegan content cluster, and campaign 2's vegan ad group. This is exactly what forced Kroma to deny vegan status despite using effera. | Product |
| L4 | Write the compliant iron sentence. | Eight launch-day keywords. "Anemia" and "iron deficiency" are blocked, and the best objection query is itself a drug claim. The door is open; nobody has written the key. | Legal + Copy |
| P4 | Sign off the product name. | Every title tag and the product URL. This research recommends Human Lactoferrin Gummies. | Brand |
Effera has self-affirmed GRAS only — and GRAS is the food pathway. A supplement ingredient not marketed in the US before 15 October 1994 requires a 75-day NDI notification, and no lactoferrin of any kind appears in the FDA NDIN list through #1460. Bovine lactoferrin has pre-1994 supplement history; yeast-derived human-sequence lactoferrin does not. This needs Legal and Helaina, and it should be confirmed directly with FDA — the current finding rests on a text-extracted PDF search where a hyphenated line break could hide a match.
No FDA warning letter to any lactoferrin marketer exists. That is not safety — lactoferrin is younger than colostrum. Palisade would enter with no enforcement floor and a real chance of being an early test case. Meanwhile kēpos is publishing at high velocity on adjacent terms. The organic window described here is real but not permanent: if kēpos turns that velocity onto these exact terms, it narrows considerably.